JP2005533775A - 糖尿病を処置するための組成物および方法 - Google Patents

糖尿病を処置するための組成物および方法 Download PDF

Info

Publication number
JP2005533775A
JP2005533775A JP2004510820A JP2004510820A JP2005533775A JP 2005533775 A JP2005533775 A JP 2005533775A JP 2004510820 A JP2004510820 A JP 2004510820A JP 2004510820 A JP2004510820 A JP 2004510820A JP 2005533775 A JP2005533775 A JP 2005533775A
Authority
JP
Japan
Prior art keywords
medicament
gastrin
composition
agent
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004510820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533775A5 (https=
Inventor
ステファン ジェイ． ブランド，
アントニオ クルズ，
Original Assignee
ワラタ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワラタ ファーマシューティカルズ， インコーポレイテッド filed Critical ワラタ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2005533775A publication Critical patent/JP2005533775A/ja
Publication of JP2005533775A5 publication Critical patent/JP2005533775A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004510820A 2002-06-07 2003-06-09 糖尿病を処置するための組成物および方法 Pending JP2005533775A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38703202P 2002-06-07 2002-06-07
US43059002P 2002-12-03 2002-12-03
PCT/US2003/018377 WO2003103701A1 (en) 2002-06-07 2003-06-09 Compositions and methods for treating diabetes

Publications (2)

Publication Number Publication Date
JP2005533775A true JP2005533775A (ja) 2005-11-10
JP2005533775A5 JP2005533775A5 (https=) 2006-07-20

Family

ID=29739925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004510820A Pending JP2005533775A (ja) 2002-06-07 2003-06-09 糖尿病を処置するための組成物および方法

Country Status (12)

Country Link
US (3) US7560425B2 (https=)
EP (1) EP1511509B1 (https=)
JP (1) JP2005533775A (https=)
KR (1) KR20050048542A (https=)
CN (1) CN1671407B (https=)
AT (2) ATE445407T1 (https=)
AU (1) AU2003243501A1 (https=)
CA (1) CA2486584A1 (https=)
DE (2) DE60316798T2 (https=)
ES (1) ES2334268T3 (https=)
IL (2) IL165285A0 (https=)
WO (1) WO2003103701A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009543859A (ja) * 2006-07-14 2009-12-10 ポステック アカデミー−インダストリー ファンデーション インシュリン分泌を増加させて血糖を減少させる表皮成長因子

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
IL156828A0 (en) 2001-01-12 2004-02-08 Waratah Pharmaceuticals Inc Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
CA2494134A1 (en) * 2002-05-24 2003-12-04 Waratah Pharmaceuticals, Inc. Treatment for diabetes
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US7560425B2 (en) 2002-06-07 2009-07-14 Waratah Pharmaceuticals Inc. Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
ATE352301T1 (de) * 2003-04-22 2007-02-15 Wyeth Corp Antineoplastische zusammensetzungen
US20080039379A1 (en) * 2003-05-27 2008-02-14 Waratah Pharmaceuticals, Inc. Compositions Comprising Gastrin Compounds and Their Use in Diabetes
US20090202494A1 (en) * 2004-01-30 2009-08-13 Antonio Cruz Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
CA2571957A1 (en) * 2004-07-01 2006-01-12 Waratah Pharmaceuticals, Inc. Methods and compositions using cd3 agonists
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
WO2006074091A2 (en) * 2004-12-30 2006-07-13 Hill's Pet Nutrition, Inc. Compositions for feline consumption
EP1951286A4 (en) * 2005-10-07 2009-11-04 Waratah Pharmaceuticals Inc COMBINED USE OF INHIBITORS OF DPP-IV AND GASTRIN COMPOUNDS
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US11311477B2 (en) * 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US8226949B2 (en) * 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) * 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) * 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
CA2732228A1 (en) * 2008-07-25 2010-01-28 The Johns Hopkins University Methods and compositions for treating and preventing autoimmune diseases
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
WO2010081015A1 (en) * 2009-01-09 2010-07-15 The Regents Of The University Of California Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening
EP4085899A1 (en) 2011-06-14 2022-11-09 Neurelis, Inc. Administration of benzodiazepine
HK1198467A1 (en) * 2011-08-03 2015-05-08 Zhongmin MA Treatment of type 2 diabetes with fty720
US20130273089A1 (en) 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
BR112014010532A2 (pt) 2011-11-03 2017-04-18 Tolera Therapeutics Inc anticorpo e métodos para inibição seletiva de respostas de célula-t
WO2014138003A1 (en) * 2013-03-04 2014-09-12 Neuralstem, Inc. Compositions comprising an immunosuppressive drug and/or neural stem cells and methods of using same for the treatment of neurodegenerative diseases and/or disorders
WO2017083555A1 (en) 2015-11-10 2017-05-18 City Of Hope Conditioning regimens and methods for inducing mixed chimerism
WO2017116569A1 (en) * 2015-12-31 2017-07-06 City Of Hope Methods for treating diabetes
US20210355448A1 (en) * 2017-06-26 2021-11-18 City Of Hope Methods of islet cell culture
IL280198B2 (en) * 2018-07-18 2026-01-01 Regenxbio Inc Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus)
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
US20240269194A1 (en) * 2021-06-10 2024-08-15 City Of Hope Compositions and methods for islet cell transplants
CN117580579A (zh) 2021-06-10 2024-02-20 纽瑞莱斯有限公司 用于治疗儿科患者的癫痫发作病症的方法和组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101353A0 (en) 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
DE69431212T2 (de) 1994-01-24 2003-04-10 The General Hospital Corp., Boston Behandlung von diabetes
US5624895A (en) * 1994-02-18 1997-04-29 Georgetown University Medical Center Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20040037818A1 (en) 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
US6610535B1 (en) 2000-02-10 2003-08-26 Es Cell International Pte Ltd. Progenitor cells and methods and uses related thereto
HU229042B1 (en) 2000-03-31 2013-07-29 Prosidion Ltd Method for the improvement of islet signaling in diabetes mellitus and for its prevention
IL156828A0 (en) * 2001-01-12 2004-02-08 Waratah Pharmaceuticals Inc Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
AU2002316811A1 (en) 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
CA2494134A1 (en) 2002-05-24 2003-12-04 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US7560425B2 (en) 2002-06-07 2009-07-14 Waratah Pharmaceuticals Inc. Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
KR20050074492A (ko) 2002-10-22 2005-07-18 와라타 파마수티컬즈, 인크. 당뇨병의 치료
US20040229810A1 (en) 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
EP1620464A1 (en) 2003-04-30 2006-02-01 Waratah Pharmaceuticals, Inc. Combined use of keratinocyte growth factor agonists and gastrin compounds
PL379145A1 (pl) 2003-05-27 2006-07-24 Waratah Pharmaceuticals, Inc. Kompozycje i sposoby obejmujące związki gastryny
US20090202494A1 (en) 2004-01-30 2009-08-13 Antonio Cruz Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
CA2571957A1 (en) 2004-07-01 2006-01-12 Waratah Pharmaceuticals, Inc. Methods and compositions using cd3 agonists
EP1951286A4 (en) 2005-10-07 2009-11-04 Waratah Pharmaceuticals Inc COMBINED USE OF INHIBITORS OF DPP-IV AND GASTRIN COMPOUNDS
EP1971363A1 (en) 2005-12-02 2008-09-24 Waratah Pharmaceuticals, Inc. Combination treatments with gastrin agonists for diabetes and related diseases
WO2007095737A1 (en) 2006-02-21 2007-08-30 Waratah Pharmaceuticals Inc. Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009543859A (ja) * 2006-07-14 2009-12-10 ポステック アカデミー−インダストリー ファンデーション インシュリン分泌を増加させて血糖を減少させる表皮成長因子

Also Published As

Publication number Publication date
US20060183674A1 (en) 2006-08-17
IL165285A0 (en) 2005-12-18
US20090269337A1 (en) 2009-10-29
DE60329724D1 (de) 2009-11-26
ATE445407T1 (de) 2009-10-15
CN1671407B (zh) 2010-05-26
DE60316798D1 (de) 2007-11-22
ATE375166T1 (de) 2007-10-15
KR20050048542A (ko) 2005-05-24
CN1671407A (zh) 2005-09-21
WO2003103701A1 (en) 2003-12-18
US7560425B2 (en) 2009-07-14
EP1511509B1 (en) 2007-10-10
DE60316798T2 (de) 2008-07-24
CA2486584A1 (en) 2003-12-18
EP1511509A4 (en) 2005-04-27
EP1511509A1 (en) 2005-03-09
IL165285A (en) 2010-04-29
AU2003243501A1 (en) 2003-12-22
ES2334268T3 (es) 2010-03-08
US20040023885A1 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
JP2005533775A (ja) 糖尿病を処置するための組成物および方法
EP1837031B1 (en) Compositions and methods for treating diabetes
US12171731B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
AU2002243501B2 (en) Composition for inducing islet neogenesis, containing gastrin/CCK receptor ligands and EGF receptor ligands
EP3132792B1 (en) Composition and methods for increasing insulin sensitivity
US20040209801A1 (en) Treatment of diabetes
US20090317372A1 (en) Small molecules for the reduction of high blood glucose level
JP2006506386A5 (https=)
US20100166675A1 (en) Pharmaceutical Composition for the Treatment of Type 1-Diabetes
WO2013050378A1 (en) Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
JP2008531730A (ja) Ｉ型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物
CN111918655B (zh) 治疗患有慢性肾脏疾病的糖尿病受试者的方法
AU2006210098A1 (en) Synergistic combination of Xolair/Omalizumab/E25 with immunosuppressive agent
CN117355297A (zh) 用于诱导褐色脂肪生成的方法和组合物
Akhtar Type 2 diabetes mellitus and Invokana: an FDA approved drug
US20250235429A1 (en) Treatment of diseases via administration of buntanetap and an antidiabetic agent
CN100577201C (zh) 糖尿病的治疗
ZA200409490B (en) Compositions and methods for treating diabetes
WO2023165479A1 (zh) 硝酮化合物或其在药学上可接受的盐与sglt-2抑制剂联合应用
HK40038946B (zh) 治疗患有慢性肾脏疾病的糖尿病受试者的方法
HK1132670A (en) Gastrin compositions and formulations, and methods of use and preparation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060531

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090205

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100223